¼ºÀÎ ±Þ¼º ¹éÇ÷º´ ȯÀÚÀÇ Ç×¾ÏÈÇпä¹ý À¯¹ß ¿À½É ±¸Åä (chemotherapy-induced nausea and vomiting) ¿¹¹æ¿¡ ÀÖ¾î¼ granisetron transdermal system patchÁ¦ÀÇ È¿°ú ºÐ¼®
The Effect of Granisetron Transdermal System Patch for the Prevention of Chemotherapy-induced Nausea and Vomiting in Adult Patients with Acute Leukemia
º´¿ø¾à»çȸÁö 2014³â 31±Ç 1È£ p.602 ~ p.609
µÎ°íÀº(Doo Ko-Eun) - ¾ÆÁÖ´ëÇб³º´¿ø ¾àÁ¦ÆÀ
ÇÑÀçÀº(Han Jae-Eun) - ¾ÆÁÖ´ëÇб³º´¿ø ¾àÁ¦ÆÀ
Àº¸í¿Â(Eun Myoung-On) - ¾ÆÁÖ´ëÇб³º´¿ø ¾àÁ¦ÆÀ
ÀÌ¿µÈñ(Lee Young-Hee) - ¾ÆÁÖ´ëÇб³º´¿ø ¾àÁ¦ÆÀ
¹ÚÁؼº(Park Joon-Seong) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
Abstract
Background : Granisetron transdermal system patch offers convenient non-invasive option and could enable continuous antiemetic effects during multi-day chemotherapy for acute leukemia patients. This study compare the effect and costs of granisetron transdermal system patch with ramosetron treatment for control chemotherapy-induced nausea and vomiting.
Methods :
Results : Total response was achieved by 51.2% of granisetron group and 45.6% of ramosetron group, but the difference not statistically significant(p=0.492). The first emetic episode occurredmedian Day1(1-9) granisetron group and median Day3(1-7) ramosetron group including patients with failure to emetic control.
Conclusions : ranisetron transdermal system patch offers reliable antiemetic effect and preferable dosing for patients receiving multi-day chemotherapy with acute leukemia, and close dosing control pharmacist is to achieve higher response.
Å°¿öµå
Granisetron transdermal patch, Chemotherapy-induced nausea and vomiting, Acute leukemia
KMID :
0869620140310010602
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)